Assay Report
Methods · Standard Curves · QC · Results
Quantify chemokine-mediated immune cell trafficking, migration, and chemotaxis using MSD multiplex panels spanning the CXCL and CCL chemokine families — from focused 6-plex mouse panels to comprehensive 13-plex human chemokine configurations, across human, mouse, and NHP.
Chemokines are the molecular navigation system of the immune system — a network of approximately 50 structurally related chemoattractant cytokines that direct leukocyte migration through concentration gradients. Unlike classical cytokines that primarily regulate immune cell activation and polarization, chemokines govern where immune cells go: CXCL chemokines (IP-10/CXCL10, IL-8/CXCL8) direct neutrophil and Th1 cell trafficking; CCL chemokines (MCP-1/CCL2, MIP-1α/CCL3, RANTES/CCL5) recruit monocytes, macrophages, and T cells. Dysregulated chemokine networks underlie the immune infiltration of tumors, the synovial inflammation of rheumatoid arthritis, the demyelinating lesions of multiple sclerosis, and the atherosclerotic plaque formation of cardiovascular disease. Dedicated chemokine panels — recognized as a distinct service category by leading CROs offering independent Chemokine Panel I product lines — capture this trafficking dimension that general cytokine panels do not adequately address.
| Panel | Plex | Chemokines | Species |
|---|---|---|---|
| Human Chemokine 11-Plex Panel 1 | 11 | Eotaxin/CCL11, Eotaxin-3/CCL26, IL-8/CXCL8, IP-10/CXCL10, MCP-1/CCL2, MCP-4/CCL13, MDC/CCL22, MIP-1α/CCL3, MIP-1β/CCL4, TARC/CCL17 | Human |
| Human Chemokine 11-Plex Panel 2 | 11 | CTACK/CCL27, ENA-78/CXCL5, Fractalkine/CX3CL1, GRO-α/CXCL1, I-309/CCL1, I-TAC/CXCL11, MIF, MIP-3α/CCL20, MIP-3β/CCL19, MIP-5/CCL15, SDF-1α/CXCL12 | Human |
| Human Chemokine 13-Plex | 13 | Eotaxin/CCL11, Eotaxin-2/CCL24, Eotaxin-3/CCL26, IL-8/CXCL8, IP-10/CXCL10, MCP-1/CCL2, MCP-2/CCL8, MCP-3/CCL7, MCP-4/CCL13, MDC/CCL22, MIP-1α/CCL3, MIP-1β/CCL4, TARC/CCL17 | Human |
| Mouse Chemokine 6-Plex | 6 | 6CKine/CCL21, BCA-1/BLC/CXCL13, MCP-5/CCL12, RANTES/CCL5, SDF-1α/CXCL12, TARC/CCL17 | Mouse |
| Mouse Chemokine 7-Plex | 7 | KC/GRO/CXCL1, IP-10/CXCL10, MCP-1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4, MIP-2/CXCL2, MIP-3α/CCL20 | Mouse |
| Mouse Chemokine 8-Plex | 8 | KC/GRO/CXCL1, IP-10/CXCL10, MCP-1/CCL2, MDC/CCL22, MIP-1α/CCL3, MIP-1β/CCL4, MIP-2/CXCL2, MIP-3α/CCL20 | Mouse |
| NHP Chemokine 10-Plex Panel 1 | 10 | Eotaxin-3/CCL26, IL-8/CXCL8, IP-10/CXCL10, MCP-1/CCL2, MCP-4/CCL13, MDC/CCL22, MIP-1α/CCL3, MIP-1β/CCL4, TARC/CCL17 | NHP |
| NHP Chemokine 10-Plex Panel 2 | 10 | Eotaxin/CCL11, Eotaxin-3/CCL26, IL-8/CXCL8, IP-10/CXCL10, MCP-1/CCL2, MCP-4/CCL13, MDC/CCL22, MIP-1α/CCL3, MIP-1β/CCL4, TARC/CCL17 | NHP |
Panel 1 covers the major inflammatory chemokine axes (CCR1–CCR5, CXCR1, CXCR3). Panel 2 covers lymphoid trafficking (CCR6, CCR7, CCR9, CCR10, CXCR4, CXCR5) plus Fractalkine/CX3CR1 and MIF. The 13-Plex combines the highest-demand analytes from both into a single panel. All services are for research use only.
Ligands: MIP-1α/CCL3, MIP-1β/CCL4, RANTES/CCL5, MCP-3/CCL7. Biology: CCR5 is the major HIV co-receptor and a therapeutic target (maraviroc). CCR1/CCR5 ligands recruit monocytes, NK cells, and Th1 cells. CCR5Δ32 mutation confers HIV resistance — a naturally occurring human gene knockout validating this axis as a therapeutic target.
Ligands: MCP-1/CCL2 (primary), MCP-2/CCL8, MCP-3/CCL7, MCP-4/CCL13. Biology: the dominant monocyte recruitment axis. MCP-1/CCR2 drives macrophage infiltration in atherosclerosis, tumor microenvironments, and adipose tissue inflammation. The most therapeutically targeted chemokine axis — CCR2 antagonists in clinical development for NASH, oncology, and fibrosis. The 13-Plex measures all four MCP family members.
Ligands: Eotaxin/CCL11, Eotaxin-2/CCL24, Eotaxin-3/CCL26. Biology: the eosinophil recruitment receptor. Eotaxins are central to allergic inflammation, asthma, eosinophilic esophagitis, and atopic dermatitis. Eotaxin-3 is the most specific and potent CCR3 ligand. The 13-Plex includes all three eotaxin family members for comprehensive Type 2 inflammation assessment.
Ligands: MDC/CCL22, TARC/CCL17. Biology: Th2 and Treg cell recruitment. MDC and TARC are elevated in atopic dermatitis, Hodgkin lymphoma, and mycosis fungoides. CCR4 is a validated therapeutic target — mogamulizumab (anti-CCR4) is approved for cutaneous T-cell lymphoma. Both ligands are included in the 11-Plex Panel 1 and 13-Plex.
Ligand: MIP-3α/CCL20. Biology: the sole CCR6 ligand — recruits Th17 cells and dendritic cells to mucosal surfaces and inflammatory sites. Central to the IL-23/IL-17/CCL20 feedback loop driving psoriasis. CCR6+ Th17 cells are the dominant pathogenic population in MS, IBD, and psoriatic arthritis. Available in the 11-Plex Panel 2.
Ligands: IP-10/CXCL10, I-TAC/CXCL11, MIG/CXCL9. Biology: the dominant Th1 and cytotoxic T-cell recruitment axis. IP-10 is one of the most consistently elevated chemokines across infection, autoimmunity, and allograft rejection. I-TAC is the highest-affinity CXCR3 ligand. Both are available in our chemokine panels — IP-10 in all human panels, I-TAC in the 11-Plex Panel 2. Measuring all three CXCR3 ligands provides the integrated chemotactic signal for this axis.
| Item | Full Service | Notes |
|---|---|---|
| Sample Processing | Included | EDTA plasma preferred |
| Standard Curve | 8-point, all chemokines | Chemokine-specific recombinant calibrators |
| QC Samples | 3 levels, duplicate | Low, medium, high across assay range |
| Data Report | Organized by receptor family | CCR/CXCR classification with per-analyte QC |
| Raw ECL Data | Included | Per-well, per-spot signal values |
For Research Use Only. Not for diagnostic procedures.
Choose Panel 1 (inflammatory axes), Panel 2 (lymphoid trafficking), 13-Plex (comprehensive), or species-specific configuration.
EDTA plasma, processed within 1 hour at 4°C. Ship on dry ice. Consistent matrix across all study samples.
Receive quantitative chemokine data organized by receptor family with QC metrics and methods documentation.
| Feature | MSD (V-PLEX Chemokine) | Luminex xMAP | Individual ELISA (×N) |
|---|---|---|---|
| Chemokine Cross-Reactivity | Minimal — spatially separated electrode spots eliminate spectral overlap between structurally related chemokines | Moderate — spectral deconvolution required for overlapping fluorophore emissions | N/A — separate wells |
| Sensitivity (LOD) | pg/mL range — low pg/mL for most chemokines | pg/mL range — variable by bead region | ~5–50 pg/mL — kit-dependent |
| Dynamic Range | 4–5 logs per analyte | 2–3 logs | 2–3 logs |
| Sample Volume (13 chemokines) | 25 µL total | 25–50 µL | 1,300 µL (100 µL × 13) |
| Lot-to-Lot Bridging | Documented — V-PLEX lot-specific datasheets | Variable — user-managed | Kit-dependent |
| Species Coverage | Human, Mouse, NHP — available per species | Human primarily; limited mouse/NHP | Human primarily |
Cytokine panels measure immune activation and polarization (Th1/Th2/Th17). Chemokine panels measure immune cell trafficking — where immune cells are being recruited. While there is some overlap (many broad cytokine panels include a few chemokines), dedicated chemokine panels provide: deeper coverage of structurally related chemokines without cross-reactivity; organization by receptor family (CCR1–CCR6, CXCR1–CXCR6) for biologically coherent interpretation; and sensitivity optimized for the low pg/mL concentrations at which chemokines operate. For research focused on cell migration, tumor immune infiltration, or chemokine receptor pharmacology, a dedicated chemokine panel provides more actionable data than a general cytokine panel.
The two panels cover complementary chemokine families. Panel 1 covers the CCR1/CCR2/CCR3/CCR4/CCR5/CXCR1/CXCR3 axes — the most commonly studied chemokine receptors in inflammation and oncology. This is the panel most frequently used as a standalone chemokine assay. Panel 2 covers the CCR6/CCR7/CCR9/CCR10/CXCR4/CXCR5/CX3CR1 axes plus MIF — extending coverage to dendritic cell trafficking (CCR6/CCR7), mucosal homing (CCR9/CCR10), hematopoiesis (CXCR4/SDF-1α), and the unique CX3CR1/Fractalkine axis. 13-Plex combines the highest-demand analytes from both into the most comprehensive single-well chemokine measurement. Choose Panel 1 for core inflammatory chemokine profiling, Panel 2 for extended trafficking coverage, or the 13-Plex for maximum receptor-axis coverage in one well.
Yes. Both require 25 µL per panel on the same MSD platform. A single plasma aliquot can support a chemokine panel (11–13 analytes) plus a cytokine panel (10–30 analytes) — 50 µL total for comprehensive immune trafficking + immune activation profiling. This is particularly valuable for studies where chemokine-directed cell migration and cytokine-mediated immune polarization are both relevant to the research question, such as tumor microenvironment characterization or autoimmune disease immunophenotyping.
EDTA plasma is preferred — the clotting process in serum collection releases platelet-derived chemokines and cytokines that can artifactually elevate certain measurements. Process within 1 hour of collection at 4°C, centrifuge at 1,500×g for 10 minutes at 4°C, aliquot into polypropylene cryovials, and freeze at −80°C. Chemokines are susceptible to freeze-thaw degradation; single-use aliquots are strongly recommended. Consistent matrix use within a study is essential — do not mix serum and plasma. For cell culture supernatant, centrifuge to remove cells and debris before freezing.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×